Weighted Average Number of Shares Outstanding, Basic of HALOZYME THERAPEUTICS, INC. from 30 Jun 2010 to 31 Dec 2025

Taxonomy & unit
us-gaap: shares
Description
Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.
Summary
HALOZYME THERAPEUTICS, INC. quarterly and annual Weighted Average Number of Shares Outstanding, Basic in shares history and change rate from 30 Jun 2010 to 31 Dec 2025.
  • HALOZYME THERAPEUTICS, INC. Weighted Average Number of Shares Outstanding, Basic for the quarter ending 31 Dec 2025 was 119,840,000, a 5.5% decline year-over-year.
  • HALOZYME THERAPEUTICS, INC. annual Weighted Average Number of Shares Outstanding, Basic for 2025 was 119,840,000, a 5.5% decline from 2024.
  • HALOZYME THERAPEUTICS, INC. annual Weighted Average Number of Shares Outstanding, Basic for 2024 was 126,827,000, a 3.9% decline from 2023.
  • HALOZYME THERAPEUTICS, INC. annual Weighted Average Number of Shares Outstanding, Basic for 2023 was 131,927,000, a 3.6% decline from 2022.
Source SEC data
View on sec.gov
Weighted Average Number of Shares Outstanding, Basic, Quarterly (shares)
Weighted Average Number of Shares Outstanding, Basic, YoY Quarterly Change (%)
Weighted Average Number of Shares Outstanding, Basic, Annual (shares)
Weighted Average Number of Shares Outstanding, Basic, YoY Annual Change (%)

HALOZYME THERAPEUTICS, INC. Quarterly Weighted Average Number of Shares Outstanding, Basic (shares)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q4 2025 119,840,000 -6,987,000 -5.5% 01 Oct 2025 31 Dec 2025 10-K 17 Feb 2026 2025 FY
Q3 2025 117,219,000 -9,631,000 -7.6% 01 Jul 2025 30 Sep 2025 10-Q 03 Nov 2025 2025 Q3
Q2 2025 121,343,000 -5,773,000 -4.5% 01 Apr 2025 30 Jun 2025 10-Q 05 Aug 2025 2025 Q2
Q1 2025 123,215,000 -3,726,000 -2.9% 01 Jan 2025 31 Mar 2025 10-Q 06 May 2025 2025 Q1
Q4 2024 126,827,000 -5,100,000 -3.9% 01 Oct 2024 31 Dec 2024 10-K 17 Feb 2026 2025 FY
Q3 2024 126,850,000 -5,115,000 -3.9% 01 Jul 2024 30 Sep 2024 10-Q 03 Nov 2025 2025 Q3
Q2 2024 127,116,000 -4,614,000 -3.5% 01 Apr 2024 30 Jun 2024 10-Q 05 Aug 2025 2025 Q2
Q1 2024 126,941,000 -8,086,000 -6% 01 Jan 2024 31 Mar 2024 10-Q 06 May 2025 2025 Q1
Q4 2023 131,927,000 -4,917,000 -3.6% 01 Oct 2023 31 Dec 2023 10-K 17 Feb 2026 2025 FY
Q3 2023 131,965,000 -4,562,000 -3.3% 01 Jul 2023 30 Sep 2023 10-Q 31 Oct 2024 2024 Q3
Q2 2023 131,730,000 -6,207,000 -4.5% 01 Apr 2023 30 Jun 2023 10-Q 06 Aug 2024 2024 Q2
Q1 2023 135,027,000 -2,631,000 -1.9% 01 Jan 2023 31 Mar 2023 10-Q 07 May 2024 2024 Q1
Q4 2022 136,844,000 -3,802,000 -2.7% 01 Oct 2022 31 Dec 2022 10-K 18 Feb 2025 2024 FY
Q3 2022 136,527,000 -5,494,000 -3.9% 01 Jul 2022 30 Sep 2022 10-Q 06 Nov 2023 2023 Q3
Q2 2022 137,937,000 -4,550,000 -3.2% 01 Apr 2022 30 Jun 2022 10-Q 08 Aug 2023 2023 Q2
Q1 2022 137,658,000 -294,000 -0.21% 01 Jan 2022 31 Mar 2022 10-Q 09 May 2023 2023 Q1
Q4 2021 140,646,000 +5,539,000 +4.1% 01 Oct 2021 31 Dec 2021 10-K 20 Feb 2024 2023 FY
Q3 2021 142,021,000 +5,443,000 +4% 01 Jul 2021 30 Sep 2021 10-Q 08 Nov 2022 2022 Q3
Q2 2021 142,487,000 +6,552,000 +4.8% 01 Apr 2021 30 Jun 2021 10-Q 09 Aug 2022 2022 Q2
Q1 2021 137,952,000 +766,000 +0.56% 01 Jan 2021 31 Mar 2021 10-Q 10 May 2022 2022 Q1
Q4 2020 135,107,000 -5,939,000 -4.2% 01 Oct 2020 31 Dec 2020 10-K 23 Feb 2021 2020 FY
Q3 2020 136,578,000 -9,558,000 -6.5% 01 Jul 2020 30 Sep 2020 10-Q 02 Nov 2021 2021 Q3
Q2 2020 135,935,000 -9,476,000 -6.5% 01 Apr 2020 30 Jun 2020 10-Q 09 Aug 2021 2021 Q2
Q1 2020 137,186,000 -7,557,000 -5.2% 01 Jan 2020 31 Mar 2020 10-Q 10 May 2021 2021 Q1
Q4 2019 141,046,000 -3,157,000 -2.2% 01 Oct 2019 31 Dec 2019 10-K 23 Feb 2021 2020 FY
Q3 2019 146,136,000 +2,187,000 +1.5% 01 Jul 2019 30 Sep 2019 10-K 23 Feb 2021 2020 FY
Q2 2019 145,411,000 +1,843,000 +1.3% 01 Apr 2019 30 Jun 2019 10-K 23 Feb 2021 2020 FY
Q1 2019 144,743,000 +2,087,000 +1.5% 01 Jan 2019 31 Mar 2019 10-K 23 Feb 2021 2020 FY
Q4 2018 144,203,000 +2,485,000 +1.8% 01 Oct 2018 31 Dec 2018 10-K 24 Feb 2020 2019 FY
Q3 2018 143,949,000 +2,759,000 +2% 01 Jul 2018 30 Sep 2018 10-K 24 Feb 2020 2019 FY
Q2 2018 143,568,000 +9,555,000 +7.1% 01 Apr 2018 30 Jun 2018 10-K 24 Feb 2020 2019 FY
Q1 2018 142,656,000 +14,041,000 +11% 01 Jan 2018 31 Mar 2018 10-K 24 Feb 2020 2019 FY
Q4 2017 141,718,000 +14,521,000 +11% 01 Oct 2017 31 Dec 2017 10-K 21 Feb 2019 2018 FY
Q3 2017 141,190,000 +13,036,000 +10% 01 Jul 2017 30 Sep 2017 10-K 21 Feb 2019 2018 FY
Q2 2017 134,013,000 +6,055,000 +4.7% 01 Apr 2017 30 Jun 2017 10-K 21 Feb 2019 2018 FY
Q1 2017 128,615,000 +1,000,000 +0.78% 01 Jan 2017 31 Mar 2017 10-K 21 Feb 2019 2018 FY
Q4 2016 127,197,000 0 0% 01 Oct 2016 31 Dec 2016 10-K 28 Feb 2017 2016 FY
Q3 2016 128,154,000 +1,233,000 +0.97% 01 Jul 2016 30 Sep 2016 10-Q 07 Nov 2017 2017 Q3
Q2 2016 127,958,000 +1,814,000 +1.4% 01 Apr 2016 30 Jun 2016 10-Q 08 Aug 2017 2017 Q2
Q1 2016 127,615,000 +2,316,000 +1.8% 01 Jan 2016 31 Mar 2016 10-Q 09 May 2017 2017 Q1
Q4 2015 127,197,000 01 Oct 2015 31 Dec 2015 10-K 29 Feb 2016 2015 FY
Q3 2015 126,921,000 +2,880,000 +2.3% 01 Jul 2015 30 Sep 2015 10-Q 07 Nov 2016 2016 Q3
Q2 2015 126,144,000 +2,434,000 +2% 01 Apr 2015 30 Jun 2015 10-Q 09 Aug 2016 2016 Q2
Q1 2015 125,299,000 01 Jan 2015 31 Mar 2015 10-Q 09 May 2016 2016 Q1
Q3 2014 124,041,000 01 Jul 2014 30 Sep 2014 10-Q 09 Nov 2015 2015 Q3
Q2 2014 123,710,000 01 Apr 2014 30 Jun 2014 10-Q 10 Aug 2015 2015 Q2
Q3 2012 112,305,002 +9,081,650 +8.8% 01 Jul 2012 30 Sep 2012 10-Q 08 Nov 2012 2012 Q3
Q2 2012 112,063,665 +9,392,255 +9.1% 01 Apr 2012 30 Jun 2012 10-Q 09 Aug 2012 2012 Q2
Q4 2011 103,406,407 01 Oct 2011 31 Dec 2011 10-K 01 Mar 2013 2012 FY
Q3 2011 103,223,352 +9,596,459 +10% 01 Jul 2011 30 Sep 2011 10-K 01 Mar 2013 2012 FY
Q2 2011 102,671,410 +10,904,611 +12% 01 Apr 2011 30 Jun 2011 10-K 01 Mar 2013 2012 FY
Q1 2011 100,927,402 01 Jan 2011 31 Mar 2011 10-K 01 Mar 2013 2012 FY
Q3 2010 93,626,893 01 Jul 2010 30 Sep 2010 10-Q 08 Nov 2011 2011 Q3
Q2 2010 91,766,799 01 Apr 2010 30 Jun 2010 10-Q 05 Aug 2011 2011 Q2

HALOZYME THERAPEUTICS, INC. Annual Weighted Average Number of Shares Outstanding, Basic (shares)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2025 119,840,000 -6,987,000 -5.5% 01 Jan 2025 31 Dec 2025 10-K 17 Feb 2026 2025 FY
2024 126,827,000 -5,100,000 -3.9% 01 Jan 2024 31 Dec 2024 10-K 17 Feb 2026 2025 FY
2023 131,927,000 -4,917,000 -3.6% 01 Jan 2023 31 Dec 2023 10-K 17 Feb 2026 2025 FY
2022 136,844,000 -3,802,000 -2.7% 01 Jan 2022 31 Dec 2022 10-K 18 Feb 2025 2024 FY
2021 140,646,000 +4,440,000 +3.3% 01 Jan 2021 31 Dec 2021 10-K 20 Feb 2024 2023 FY
2020 136,206,000 -8,123,000 -5.6% 01 Jan 2020 31 Dec 2020 10-K 21 Feb 2023 2022 FY
2019 144,329,000 +730,000 +0.51% 01 Jan 2019 31 Dec 2019 10-K 22 Feb 2022 2021 FY
2018 143,599,000 +7,180,000 +5.3% 01 Jan 2018 31 Dec 2018 10-K 23 Feb 2021 2020 FY
2017 136,419,000 +8,455,000 +6.6% 01 Jan 2017 31 Dec 2017 10-K 24 Feb 2020 2019 FY
2016 127,964,000 +1,260,000 +0.99% 01 Jan 2016 31 Dec 2016 10-K 21 Feb 2019 2018 FY
2015 126,704,000 01 Jan 2015 31 Dec 2015 10-K 20 Feb 2018 2017 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.